Clinical Trial

Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.

Study acronym: NEUROBLASTOTEP
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goals of the NEUROBLASTOTEP trial is to compare the diagnostics performance of a the 18F-metafluorobenzylguanidine (18F-MFBG) Positron Emission Tomography / Computed Tomography scan (PET/CT) compared to 123I-metaiodobenzylguanidine (123I-MIBG scintigraphy (current gold standard) for imaging in neuroblastoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-31.
Trial Details
NCT Number NCT07111117
Lead Sponsor Institut Curie
Conditions Neuroblastoma
Enrollment 30 participants
Start Date 2026-03-01
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-03